Table 1.
Characteristics of patients
| Group | Control (n = 10) | Gln (n = 10) | Gln plus ED (n = 10) | |
|---|---|---|---|---|
| Regimen | DCF | 4 | 4 | 5 |
| DGS | 6 | 6 | 5 | |
| Daily calorie intake including ED (kcal) | 2100 | 2100 | 2100 | |
| (1800–2100) | (1600–2100) | (2100–2100) | ||
| Age (years) | 68 | 73.5 | 75 | |
| 49–82 | 68–78 | 58–83 | ||
| Sex | Female | 1 | 3 | 0 |
| Male | 9 | 7 | 10 | |
| Cancer site | Ce 1, Lt 3, Mt 6 | Ae 1, Lt 2, Mt 4, Mt-Ut 2, Ut 1 | Lt 2, Mt 8 | |
| Radiation | Yes | 0 | 0 | 0 |
| No | 10 | 10 | 10 | |
| Stage | II | 2 | 4 | 1 |
| III | 4 | 1 | 5 | |
| IVa | 3 | 3 | 0 | |
| IVb | 1 | 2 | 4 | |
| BMI | 21.75 (18.37–25.59) | 22.42 (16.60–25.20) | 21.08 (14.60–24.20) | |
Ae abdominal esophageal site, BMI body mass index, Ce cervical esophageal site, DCF docetaxel + cisplatin + 5-fluorouracil, DGS docetaxel + nedaplatin + S-1, ED elemental diet, Gln glutamine, Lt lower thoracic esophageal site, Mt middle thoracic esophageal site, Ut upper thoracic esophageal site